MedPath

Photobiomodulation for Dry Age Related Macula Degeneration

Not Applicable
Not yet recruiting
Conditions
Photobiomodulation
Age-Related Macular Degeneration
Interventions
Device: Valeda machine
Registration Number
NCT05507840
Lead Sponsor
Oslo University Hospital
Brief Summary

The study will investigate the effect of photobiomodulation treatment on the risk of developing late age related macula degeneration (AMD) in the study eye in patients with wet AMD in the fellow eye.

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
121
Inclusion Criteria
  • patients with dry AMD in the study eye and wet AMD in the control eye
Exclusion Criteria
  • Geographic atrophy of the central macular region at enrolment
  • Previous/ active wet AMD in the study eye
  • A history of epilepsy
  • Retinal diseases apart from AMD
  • Significant media opacities
  • Cataracts worse than grade 2 (LOCS III classification)
  • Change in AREDS 2 supplements (vitamins) 1 month before the study and during the study trial was allowed.
  • Ongoing systemic medications that are photosensitizing (e.g. tetracyclins)
  • Systemic medications during the last 6 months that can cause deposits in the macular region (hydroxychloroquine, amiodarone)
  • Unable to give informed consent
  • Unable to cooperate with the treatment and follow-up

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
InterventionValeda machineNear or infra red light provided by the Valeda machine will be applied in the intervention eye
ControlValeda machineLight with very low intensity provided by the same Valeda machine will be applied in the control eye
Primary Outcome Measures
NameTimeMethod
Percentage of patients that develope late AMD in the study eye compared with control after 3 years of follow-up3 years
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath